Alcohol Use Disorder
617
142
184
283
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Published Results
137 trials with published results (22%)
Research Maturity
283 completed trials (46% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
3.9%
24 terminated out of 617 trials
92.2%
+5.7% vs benchmark
6%
35 trials in Phase 3/4
48%
137 of 283 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 283 completed trials
Clinical Trials (617)
Environment and Alcohol: A Pilot Study
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 1
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2
Hepatic Lipid Metabolism-Alcohol Use Disorder
Spironolactone in Alcohol Use Disorder (SAUD)
Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder
Addictions Neuroclinical Assessment (ANA)
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
CM for Patients With ALD After Liver Transplant
Implementation Facilitation Pilot for Alcohol Use Disorder (AUD) in Alcohol-associated Liver Disease (ALD)
Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B)
Leveraging Virtual Care Strategies to Improve Access and Treatment for Individuals With Alcohol Use Disorders
Oxytocin to Enhance Integrated Treatment for AUD and PTSD
Study of NTX-2001 on Alcohol Consumption in Alcohol Use Disorder
Human Laboratory Study of Apremilast for Alcohol Use Disorder
rTMS Target Identification for Functional Disability in AUD+mTBI
Semaglutide Therapy for Alcohol Reduction (STAR)
tAN for Substance Use Disorder
Screening, Evaluation and Assessment (SEA) Protocol at the NIDA IRP
NIAAA Natural History Protocol